Request an Annual Quote
The government alleges that Alexander Baldonado received kickbacks from a lab representative and others for approving orders for tests billed to Medicare.
News items for the week of Feb. 19, 2024.
Veracyte reported Q4 revenues of $98.2 million driven by strong sales of its Afirma thyroid cancer and Decipher prostate cancer tests.
The company saw nearly 40 percent growth in test volume in 2023 and expects full-year 2024 revenue to grow between 16 and 19 percent.
The ColoAlert stool test combines PCR-based DNA and RNA analysis with fecal immunohistochemistry for the early detection of colorectal cancer and precancerous lesions.
The pilot study from the network will explore the feasibility of using multi-cancer detection tests in randomized studies.
Bryant will be replaced by an "Office of the CEO" consisting of interim CEO Michael Iskra, President Robert Bujarski, and others.
The company, which recently laid off about 10 percent of its workforce as part of a cost-cutting initiative, reported strong growth in revenues from its exome and genome tests.
The University of Birmingham spinout will use the funding to support R&D for its multiomic platform for finding biomarkers for cancer and other diseases.
The program combines the Camtech Health HPV test for self-collection with the BD Onclarity HPV assay to improve the rate of cervical cancer screening.